News

News

03/18/2019
BOULDER, Colo. , March 18, 2019 /PRNewswire/ --  Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI ® in combination with MEKTOVI ®
01/14/2019
- Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium - - Updated confirmed ORR remains 48% and updated median PFS remains 8.0 months - - Investor webcast will be held on Tuesday, January 15 at 9:00 AM ET - BOULDER, Colo. , Jan. 14, 2019 /PRNewswire/ -- Array BioPharma Inc.
Displaying 11 - 16 of 16